- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Parexel teams with MyEyeDr. to increase patient access and participation in ophthalmology clinical trials
The company’s collaboration leverages MyEyeDr.’s 850+ offices across the United States to refer patients into ophthalmology and other therapeutic area clinical trials, expands Parexel’s Community Alliance Network to bring trials to patients where they are.
Parexel and MyEyeDr. are currently collaborating on recruitment for a diabetic retinopathy clinical trial with future plans to expand into additional therapeutic areas such as endocrinology.
Parexel has announced a formal agreement with MyEyeDr., a vision healthcare organization, to refer its patients into existing and future ophthalmology clinical trials.
According to a news release, Parexel and MyEyeDr. are currently collaborating on recruitment for a diabetic retinopathy clinical trial with future plans to expand into additional therapeutic areas such as endocrinology.
“Meeting patients where they already are — such as centers providing annual routine eye exams and other vision care — is vital to the development of new therapies,” Clare Grace, PhD, chief patient officer for Parexel, said in a news release. “By fostering relationships with the broader healthcare community, we’re able to raise awareness and ensure more patients are exposed to clinical research as a care option, in turn increasing our reach for clinical trial recruitment and, ultimately, speeding the availability of life-changing treatments.”
Through the collaboration, Parexel and MyEyeDr. will partner on recruitment of patients for a wide variety of ophthalmology indications, including macular degeneration, one of the leading causes of visual disability worldwide. By leveraging MyEyeDr.’s 850+ offices across 28 states, the companies will be able to disseminate information directly to the types of patients needed for ophthalmology studies with opportunities for expansion into other adjacent therapeutic areas. MyEyeDr. is owned by Capital Vision Services, LP, which manages independently-owned optometry practices operating under the trade name MyEyeDr.
Under the agreement, MyEyeDr. will be part of Parexel’s Community Alliance Network, a novel program launched in June further integrating clinical research into the community healthcare setting to better serve patients and in turn create further opportunity for increased diversity in clinical trials. MyEyeDr joins CVS Health, the leading health care solutions company, and Javara, the leading Integrated Research Organization, as members of the network.
